Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Peak Bio, Inc.

Peak Bio, Inc. develops innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer.

Peak Bio Inc. | 789 followers on LinkedIn. Clinical-stage biopharmaceutical company. #PKBO | Our goal is to find innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer.

Notice to recruiters

All recruitment vendors (temporary staffing agencies, placement services, and professional recruiters) are prohibited from contacting our employees.

In order to be an authorized vendor partner for Peak Bio, all such organizations must have a formal written agreement with Peak Bio’s Human Resources Department. 

pH Pharma Inc. Director

신용남

Associate Director at pH Pharma Co., Ltd.

	Dec '21	Dec '22	Dec '23
net income	-8.29M -	-13.09M 57.84%	-12.83M 2.01%
depreciation and amortization	176.65K -	786.48K 345.22%	311.12K 60.44%
deferred income tax		-816.04B -
stock based compensation	4.89K -	560.06K 11,353.17%	275.42K 50.82%
change in working capital	93.08K -	2.37M 2,445.86%	3.66M 54.44%
accounts receivables			-68.16 -
inventory
accounts payables	-427.33K -	816.04K 290.96%	2.23M 173.87%
other working capital	520.41K -	1.55M 198.56%	-14.33 100.00%
other non cash items	-846.27K -	816.04B 96,427,708.50%	3.15M 100.00%
net cash provided by operating activities	-8.86M -	-7.49M 15.55%	-4.76M 36.44%
investments in property plant and equipment	-9.88K -	-142.25K 1,339.77%	-2.72 100.00%
acquisitions net			-97.51 -
purchases of investments
sales maturities of investments
other investing activites			0.00 -
net cash used for investing activites	-9.88K -	-142.25K 1,339.77%	-100.23 99.93%
debt repayment		-173.64K -	-3.44M 1,878.59%
common stock issued	6.39M -	5.18M 19.01%	105.32K 97.97%
common stock repurchased
dividends paid
other financing activites	1.99M -	3.13M 57.18%	-289.58K 109.25%
net cash used provided by financing activities	8.39M -	8.14M 2.98%	4.28M 47.37%
effect of forex changes on cash	521.71K -	-55.23K 110.59%	23.79K 143.08%
net change in cash	32.61K -	452.11K 1,286.43%	-452.94K 200.18%
cash at beginning of period	409.87K -	442.48K 7.96%	894.59K 102.18%
cash at end of period	442.48K -	894.59K 102.18%	441.65K 50.63%
operating cash flow	-8.86M -	-7.49M 15.55%	-4.76M 36.44%
capital expenditure	-9.88K -	-142.25K 1,339.77%	-2.72 100.00%
free cash flow	-8.87M -	-7.63M 14.04%	-4.76M 37.62%

COM:PEAK-BIO

Peak Bio, Inc.

Last Close

0.05

14/11 20:00

Market Cap

192.60K

Beta: -

Volume Today

1.93K

Avg: -

Preview